• CROI: Clinical Pharmacology at CROI 2022 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/28/22)
   
  
• CROI: CROI 2022 and HIV prevention - NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington (03/28/22)
   
  
• CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany (03/21/22)
   
  
• CROI: HIV Prevention and Resistance on PrEP - By Christina K. Psomas MD PhD - (04/20/22)
   
  
• Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies - (05/24/22)
   
  
• Molnupiravir for the Treatment of COVID-19 in Immunocompromised Patients: Efficacy, Safety, and Virology Results from the Phase 3 MOVe-OUT Trial - (05/24/22)
   
  
• CROI: Increased Physical Strength is Associated with Improved Brain Integrity in Older People Living with HIV - (05/23/22)
   
  
More HIV Articles...
 

More News Updates Articles...
 

• EASL: HCV Micro-Elimination Funding Grants Available
   
  
• EASL: Summary from EASL 2021 for Hepatitis B, C, D and fatty liver disease. Liver disease in 2021: advances and remaining challenges. Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (07/25/21)
   
  
• The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era Within a US Health Claims Database - (05/23/22)
   
  
• The Effects on Plaque of Statins & PCSK9 Inhibitors - (05/17/22)
   
  
• Louisiana's HCV Elimination Plan- ("Netflix" Model) - (04/27/22)
   
  
• Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission. - (04/20/22)
   
  
• HCV Treatments in 2020 new data; HCV Death Rates: Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014-2020 - (04/06/22)
   
  
More Hep C Articles...
 

• FDA Guidance for Industry - Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment - (04/26/22)
   
  
• ATI-2173 Monotherapy Results in Prolonged Off-Treatment Suppression in HBV DNA and RNA - (04/08/22)
   
  
• SAVE-1: Phase 2 Results of a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), ATI-2173 + TDF in HBV-Infected Patients - (04/08/22)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.